AP NEWS

Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com

June 13, 2018

DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering.

Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Key Topics Covered:

1. Key Insights

2. IPF Market Overview at a Glance

2.1. Market Share (%) Distribution of IPF in 2017

2.2. Market Share (%) Distribution of IPF in 2027

3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)

3.1. Introduction

3.2. Staging of IPF

3.3. Risk Factors & Disease Causes

3.4. Symptoms

3.5. Pathogenesis

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7 MM Prevalent Population of IPF

4.3. Country Wise-Epidemiology of IPF

5. Current Treatment Practices

5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)

6. Unmet needs

7. Marketed Products

7.1. Esbriet (Pirfenidone): InterMune Inc.

7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG

8. Emerging Therapies

9. Key Cross Competition

10. Phase III Drugs

10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation

11. Phase II Drugs

11.1. CC-90001: Celgene Corporation

11.2. Gefapixant: Merck & Co., Inc.

11.3. GLPG1690: Galapagos NV

11.4. LT-1001: LTT Bio-Pharma

11.5. BG00011: Biogen Inc.

11.6. BMS-986020: Bristol-Myers Squibb

11.7. LT-1002: Chong Kun Dang Pharmaceutical

11.8. Pamrevlumab: FibroGen

11.9. PBI4050: ProMetic Life Sciences

11.10. PRM 151: Promedior, Inc.

11.11. Tipelukast: MediciNova

11.12. TD139: Bristol-Myers Squibb

11.13. VAY736: Novartis

11.14. TAS-115: Taiho Pharmaceutical

12. IPF: Market Analysis

12.1. Key Findings

12.2. Total Market Size of IPF in 7 MM

12.3. Therapy Based Market Size of IPF in 7 MM

13. Market Size of IPF by Country

14. Market Drivers of IPF

15. Market Barriers of IPF

16. Appendix

16.1. Report Methodology

17. Capabilities

For more information about this report visit https://www.researchandmarkets.com/research/slfg3c/idiopathic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006229/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/13/2018 04:51 PM/DISC: 06/13/2018 04:51 PM

http://www.businesswire.com/news/home/20180613006229/en

AP RADIO
Update hourly